Epicardial Adipose Tissue (EAT) thickness is associated with cardiovascular and liver damage in nonalcoholic fatty liver disease

PLoS ONE

Volumn 11, Issue 9, 2016, Pages

  Fracanzani, Anna Ludovica ^a   Pisano, Giuseppina ^a   Consonni, Dario ^a   Tiraboschi, Silvia ^a   Baragetti, Andrea ^a   Bertelli, Cristina ^a   Norata, Giuseppe Danilo ^a   Dongiovanni, Paola ^a   Valenti, Luca ^a   Grigore, Liliana ^b   Tonella, Tatiana ^c   Catapano, Alberico ^a   Fargion, Silvia ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Bassini Hospital   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGE; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD VESSEL INJURY; BODY MASS; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG USE; ECHOGRAPHY; EPICARDIAL FAT; FEMALE; GENETIC RISK; HUMAN; HUMAN TISSUE; HYPERTENSION; LIVER BIOPSY; LIVER FIBROSIS; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NONALCOHOLIC FATTY LIVER; SEX DIFFERENCE; SMOKING; WAIST CIRCUMFERENCE; ADIPOSE TISSUE; AGED; LIVER; MIDDLE AGED; PATHOLOGY; PERICARDIUM;

ADIPOSE TISSUE; AGED; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LIVER; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PERICARDIUM;

EID: 84990940987     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0162473     Document Type: Article

References (63)

1. Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. Clinics in liver disease. 2007; 11(1):1-16, vii. doi: 10.1016/j.cld.2007.02.009 PMID: 17544968.
2. Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, et al. Long-termfollow-up of patients with nonalcoholic fatty liver. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association. 2009; 7(2):234-8. doi: 10.1016/j.cgh.2008.11.005 PMID: 19049831.
3. Serfaty L, Lemoine M. Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis. Diabetes & metabolism. 2008; 34(6 Pt 2):634-7. doi: 10.1016/S1262-3636(08) 74597-X PMID: 19195623.
4. Lonardo A, BallestriS, Marchesini G, Angulo P, Loria P. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2015; 47(3):181-90. doi: 10.1016/j.dld. 2014.09.020 PMID: 25739820.
5. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. The New England journal of medicine. 2010; 363(14):1341-50. doi: 10.1056/NEJMra0912063 PMID: 20879883.
6. Sookoian S, Pirola CJ. Non-Alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. Journal of hepatology. 2008; 49(4):600-7. doi: 10.1016/j.jhep.2008.06.012 PMID: 18672311.
7. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-termfollowup of patients with NAFLD and elevated liver enzymes. Hepatology. 2006; 44(4):865-73. doi: 10.1002/hep.21327 PMID: 17006923.
8. ArmstrongMJ, Adams LA, Canbay A, Syn WK. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology. 2014; 59(3):1174-97. doi: 10.1002/hep.26717 PMID: 24002776.
9. Valenti L, Al-Serri A, Daly AK, Galmozzi E, Rametta R, Dongiovanni P, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphisminfluences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2010; 51(4):1209-17. doi: 10.1002/hep.23622 PMID: 20373368.
10. Petta S, Valenti L, Marchesini G, Di Marco V, Licata A, CammaC, et al. PNPLA3GG genotype and carotid atherosclerosis in patients with non-Alcoholic fatty liver disease. PloS one. 2013; 8(9):e74089. doi: 10.1371/journal.pone.0074089 PMID: 24069270; PubMed Central PMCID: PMC3775795.
11. Altin C, Sade LE, Gezmis E, Ozen N, Duzceker O, Bozbas H, et al. Assessment of Subclinical Atherosclerosis by Carotid Intima-Media Thickness and Epicardial Adipose Tissue Thickness in Prediabetes. Angiology. 2016. doi: 10.1177/0003319716643669 PMID: 27069111.
12. Sinha SK, Thakur R, Jha MJ, Goel A, Kumar V, Kumar A, et al. Epicardial Adipose Tissue Thickness and Its Association With the Presence and Severity of Coronary ArteryDisease in Clinical Setting: A Cross-Sectional Observational Study. Journal of clinical medicine research. 2016; 8(5):410-9. doi: 10. 14740/jocmr2468w PMID: 27081428; PubMed Central PMCID: PMC4817582.
13. Iacobellis G, Bianco AC. Epicardial adipose tissue: emerging physiological, pathophysiological and clinical features. Trends in endocrinology and metabolism: TEM. 2011; 22(11):450-7. doi: 10.1016/j. tem.2011.07.003 PMID: 21852149.
14. Malavazos AE, Di Leo G, Secchi F, Lupo EN, Dogliotti G, Coman C, et al. Relation of echocardiographic epicardial fat thickness andmyocardial fat. The American journal of cardiology. 2010; 105 (12):1831-5. doi: 10.1016/j.amjcard.2010.01.368 PMID: 20538139.
15. Perseghin G, Lattuada G, De Cobelli F, Esposito A, Belloni E, Ntali G, et al. Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology. 2008; 47(1):51-8. doi: 10.1002/hep.21983 PMID: 17955548.
16. Graner M, Nyman K, Siren R, Pentikainen MO, Lundbom J, Hakkarainen A, et al. Ectopic fat depots and left ventricular function in nondiabetic men with nonalcoholic fatty liver disease. Circulation Cardiovascular imaging. 2015; 8(1). doi: 10.1161/CIRCIMAGING.114.001979 PMID: 25550397.
17. Mahabadi AA, Berg MH, Lehmann N, Kalsch H, Bauer M, Kara K, et al. Association of epicardial fat with cardiovascular risk factors and incidentmyocardial infarction in the general population: the Heinz Nixdorf Recall Study. Journal of the American College of Cardiology. 2013; 61(13):1388-95. doi: 10. 1016/j.jacc.2012.11.062 PMID: 23433560.
18. Nakazato R, Dey D, Cheng VY, Gransar H, Slomka PJ, Hayes SW, et al. Epicardial fat volume and concurrent presence of bothmyocardial ischemia and obstructive coronary arterydisease. Atherosclerosis. 2012; 221(2):422-6. doi: 10.1016/j.atherosclerosis.2011.12.018 PMID: 22305262.
19. Khawaja T, GreerC, Chokshi A, Chavarria N, Thadani S, Jones M, et al. Epicardial fat volume in patients with left ventricular systolic dysfunction. The American journal of cardiology. 2011; 108 (3):397-401. doi: 10.1016/j.amjcard.2011.03.058 PMID: 21565323.
20. Iacobellis G, Corradi D, SharmaAM. Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart. Nature clinical practice Cardiovascular medicine. 2005; 2(10):536-43. doi: 10.1038/ncpcardio0319 PMID: 16186852.
21. Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, Arafat H, et al. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation. 2003; 108(20):2460-6. doi: 10.1161/01.CIR. 0000099542.57313.C5 PMID: 14581396.
22. Kremen J, Dolinkova M, Krajickova J, Blaha J, Anderlova K, Lacinova Z, et al. Increased subcutaneous and epicardial adipose tissue production of proinflammatory cytokines in cardiac surgery patients: possible role in postoperative insulin resistance. The Journal of clinical endocrinology and metabolism. 2006; 91(11):4620-7. doi: 10.1210/jc.2006-1044 PMID: 16895955.
23. Baker AR, Harte AL, Howell N, Pritlove DC, Ranasinghe AM, da Silva NF, et al. Epicardial adipose tissue as a source of nuclear factor-kappaB and c-Jun N-terminal kinase mediated inflammation in patients with coronary arterydisease. The Journal of clinical endocrinology and metabolism. 2009; 94 (1):261-7. doi: 10.1210/jc.2007-2579 PMID: 18984670.
24. Fitzgibbons TP, Czech MP. Epicardial and perivascular adipose tissues and their influence on cardiovascular disease: basic mechanisms and clinical associations. Journal of the American Heart Association. 2014; 3(2):e000582. doi: 10.1161/JAHA.113.000582 PMID: 24595191; PubMed Central PMCID: PMC4187500.
25. Corrao S, Rinollo C, Scaglione R. Non-Alcoholic fatty liver disease: severity of fibrosis and its relationships with clinical and biological variables. Journal of hepatology. 2015; 62(5):1212-3. doi: 10.1016/j. jhep.2015.01.010 PMID: 25617498.
26. Ulucan S, Katlandur H, Kaya Z. Epicardial fat and liver disease; the contribution of cardio autonomic nervous system function. Journal of hepatology. 2015; 62(5):1214. doi: 10.1016/j.jhep.2015.01.008 PMID: 25620397.
27. Alp H, Karaarslan S, Selver Eklioglu B, Atabek ME, Altin H, Baysal T. Association between nonalcoholic fatty liver disease and cardiovascular risk in obese children and adolescents. The Canadian journal of cardiology. 2013; 29(9):1118-25. doi: 10.1016/j.cjca.2012.07.846 PMID: 23040432.
28. Iacobellis G, Barbarini G, Letizia C, Barbaro G. Epicardial fat thickness and nonalcoholic fatty liver disease in obese subjects. Obesity. 2014; 22(2):332-6. doi: 10.1002/oby.20624 PMID: 24115757.
29. Sunbul M, Agirbasli M, Durmus E, Kivrak T, Akin H, Aydin Y, et al. Arterial stiffness in patients with nonalcoholic fatty liver disease is related to fibrosis stage and epicardial adipose tissue thickness. Atherosclerosis. 2014; 237(2):490-3. doi: 10.1016/j.atherosclerosis.2014.10.004 PMID: 25463079.
30. Petta S, Argano C, Colomba D, CammaC, Di Marco V, Cabibi D, et al. Epicardial fat, cardiac geometry and cardiac function in patients with non-Alcoholic fatty liver disease: association with the severity of liver disease. Journal of hepatology. 2015; 62(4):928-33. doi: 10.1016/j.jhep.2014.11.030 PMID: 25445395.
31. Diabetes AATFoI. American College of Endocrinology and American Diabetes Association Consensus statement on inpatient diabetes and glycemic control. Diabetes care. 2006; 29(8):1955-62. doi: 10. 2337/dc06-9913 PMID: 16873812.
32. National Cholesterol Education Program ExpertPanel on Detection E, Treatment of High Blood Cholesterol in A. Third Report of the National Cholesterol Education Program (NCEP) ExpertPanel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143-421. PMID: 12485966.
33. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: Executive Summary. Critical pathways in cardiology. 2005; 4(4):198-203. PMID: 18340209.
34. Echouffo-Tcheugui JB, Kengne AP. Comparative performance of diabetes-specific and general population-based cardiovascular risk assessment models in people with diabetes mellitus. Diabetes & metabolism. 2013; 39(5):389-96. doi: 10.1016/j.diabet.2013.07.002 PMID: 24080092.
35. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC gastroenterology. 2006; 6:33. doi: 10.1186/1471-230X-6-33 PMID: 17081293; PubMed Central PMCID: PMC1636651.
36. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Annals of internal medicine. 2005; 143(10):722-8. PMID: 16287793.
37. Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-Analysis. Hepatology. 2011; 54 (3):1082-90. doi: 10.1002/hep.24452 PMID: 21618575; PubMed Central PMCID: PMC4197002.
38. Folsom AR, Eckfeldt JH,Weitzman S, Ma J, Chambless LE, BarnesRW, et al. Relation of carotid artery wall thickness to diabetes mellitus, fasting glucose and insulin, body size, and physical activity. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Stroke; a journal of cerebral circulation. 1994; 25(1):66-73. PMID: 8266385.
39. MukherjeeD, Yadav JS. Carotid arteryintimal-medial thickness: indicator of atherosclerotic burden and response to risk factor modification. American heart journal. 2002; 144(5):753-9. PMID: 12422142.
40. Stein JH, Fraizer MC, Aeschlimann SE, Nelson-Worel J, McBride PE, Douglas PS. Vascular age: integrating carotid intima-media thickness measurements with global coronary risk assessment. Clinical cardiology. 2004; 27(7):388-92. PMID: 15298037.
41. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification. European journal of echocardiography: the journal of theWorking Group on Echocardiography of the European Society of Cardiology. 2006; 7(2):79-108. doi: 10.1016/j.euje.2005. 12.014 PMID: 16458610.
42. Licata G, Scaglione R, Corrao S, Ganguzza A, Mazzola G, ArnoneS, et al. Heredity and obesity-Associated hypertension: impact of hormonal characteristics and left ventricular mass. Journal of hypertension. 1995; 13(6):611-8. PMID: 7594417.
43. de Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, de DivitiisO, et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. Journal of the American College of Cardiology. 1992; 20(5):1251-60. PMID: 1401629.
44. Nagueh SF, Appleton CP, GillebertTC, Marino PN, Oh JK, SmisethOA, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Journal of the American Society of Echocardiography: official publication of the American Society of Echocardiography. 2009; 22 (2):107-33. doi: 10.1016/j.echo.2008.11.023 PMID: 19187853.
45. Iacobellis G, Assael F, RibaudoMC, Zappaterreno A, Alessi G, Di MarioU, et al. Epicardial fat from echocardiography: a new method for visceral adipose tissue prediction. Obesity research. 2003; 11 (2):304-10. doi: 10.1038/oby.2003.45 PMID: 12582228.
46. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 2007; 46(1):32-6. doi: 10.1002/hep.21669 PMID: 17567829.
47. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007; 45(4):846-54. doi: 10.1002/hep.21496 PMID: 17393509.
48. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41(6):1313-21. doi: 10.1002/hep.20701 PMID: 15915461.
49. Psychari SN, Rekleiti N, Papaioannou N, Varhalama E, Drakoulis C, Apostolou TS, et al. Epicardial Fat in Nonalcoholic Fatty Liver Disease: Properties and Relationships With Metabolic Factors, Cardiac Structure, and Cardiac Function. Angiology. 2016; 67(1):41-8. doi: 10.1177/0003319715576672 PMID: 25818101.
50. Colak Y, Karabay CY, Tuncer I, Kocabay G, Kalayci A, Senates E, et al. Relation of epicardial adipose tissue and carotid intima-media thickness in patients with nonalcoholic fatty liver disease. European journal of gastroenterology& hepatology. 2012; 24(6):613-8. doi: 10.1097/MEG.0b013e3283513f19 PMID: 22495402.
51. Drapkina J, DrapkinaO. Epicardial fat as the predictor for essential hypertension and early vascular damage in patients with metabolic syndrome and non-Alcoholic fatty liver disease. Endoscopic ultrasound. 2014; 3(Suppl 1):S2. PMID: 26425524; PubMed Central PMCID: PMC4569924.
52. Topuz M, Dogan A, Celik A, Can C, Ozdogru I, Kemal Eryol N. Investigation of the relationship between non-Alcoholic fatty liver disease and coronary arterydisease. La Clinica terapeutica. 2014; 165(1):e46-51. doi: 10.7417/CT.2014.1671 PMID: 24589960.
53. Kaya H, ErtasF, Oylumlu M, Bilik MZ, Yildiz A, Yuksel M, et al. Relation of epicardial fat thickness and brachial flow-mediated vasodilation with coronary arterydisease. Journal of cardiology. 2013; 62 (6):343-7. doi: 10.1016/j.jjcc.2013.05.009 PMID: 23810068.
54. Natale F, Tedesco MA, Mocerino R, de Simone V, Di Marco GM, Aronne L, et al. Visceral adiposity and arterial stiffness: echocardiographic epicardial fat thickness reflects, better than waist circumference, carotid arterial stiffness in a large population of hypertensives. European journal of echocardiography: the journal of theWorking Group on Echocardiography of the European Society of Cardiology. 2009; 10(4):549-55. doi: 10.1093/ejechocard/jep002 PMID: 19211568.
55. Iacobellis G. Epicardial fat: a new cardiovascular therapeutic target. Current opinion in pharmacology. 2016; 27:13-8. doi: 10.1016/j.coph.2016.01.004 PMID: 26848943.
56. Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. The New England journal of medicine. 2014; 371(23):2237-8. doi: 10.1056/NEJMc1412427 PMID: 25470706.
57. Iacobellis G, Malavazos AE, Corsi MM. Epicardial fat: from the biomolecular aspects to the clinical practice. The international journal of biochemistry& cell biology. 2011; 43(12):1651-4. doi: 10.1016/j.biocel. 2011.09.006 PMID: 21967993.
58. Targher G, Bertolini L, Tessari R, Zenari L, Arcaro G. Retinopathy predicts future cardiovascular events among type 2 diabetic patients: The Valpolicella Heart Diabetes Study. Diabetes care. 2006; 29 (5):1178. doi: 10.2337/diacare.2951178 PMID: 16644664.
59. Targher G, Bertolini L, Rodella S, Lippi G, Zoppini G, Chonchol M. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clinical journal of the American Society of Nephrology: CJASN. 2010; 5(12):2166-71. doi: 10.2215/CJN.05050610 PMID: 20724519; PubMed Central PMCID: PMC2994076.
60. Luna-Luna M, Medina-Urrutia A, Vargas-Alarcon G, Coss-Rovirosa F, Vargas-Barron J, Perez-Mendez O. Adipose Tissue in Metabolic Syndrome: Onset and Progression of Atherosclerosis. Archives of medical research. 2015; 46(5):392-407. doi: 10.1016/j.arcmed.2015.05.007 PMID: 26009250.
61. Baragetti A, Pisano G, BertelliC, Garlaschelli K, Grigore L, Fracanzani AL, et al. Subclinical atherosclerosis is associated with Epicardial Fat Thickness and hepatic steatosis in the general population. Nutrition, metabolism, and cardiovascular diseases: NMCD. 2016; 26(2):141-53. doi: 10.1016/j. numecd.2015.10.013 PMID: 26777475.
62. Dongiovanni P, Petta S, MaglioC, Fracanzani AL, Pipitone R, Mozzi E, et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology. 2015; 61(2):506-14. doi: 10.1002/hep.27490 PMID: 25251399.
63. Xia MF, Ling Y, Bian H, Lin HD, Yan HM, Chang XX, et al. I148M variant of PNPLA3 increases the susceptibility to non-Alcoholic fatty liver disease caused by obesity and metabolic disorders. Alimentary pharmacology & therapeutics. 2016; 43(5):631-42. doi: 10.1111/apt.13521 PMID: 26765961.